Hypocrellin A
Based on 2 publication(s) in Google Scholar
Hypocrellin A is a PKC inhibitor that exerts antidiabetic activity by reversing the effects of high glucose on endothelin (ET-1) expression. Hypocrellin A is also a photosensitizer for photodynamic therapy (PDT) with anticancer, antibacterial and antiviral activities, especially against human immunodeficiency virus (HIV). In addition, Hypocrellin-A also possesses anti-Leishmania activity (IC50=0.27 μg/ml).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.73%
- CAS No.: 77029-83-5
- Formule: C30H26O10
- Masse moléculaire:546.52
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Differentiation Inducing Compound Library
HY-L038
-
Reprogramming Compound Library
HY-L039
-
Anti-diabetic Compound Library
HY-L040
-
Oxygen Sensing Compound Library
HY-L045
-
Antibacterial Compound Library
HY-L049
-
Phenols Library
HY-L057
-
Cytoskeleton Compound Library
HY-L060
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Antiparasitic Compound library
HY-L082
-
Microbial Metabolite Library
HY-L084
-
Angiogenesis-Related Compound Library
HY-L088
-
Mitochondria-Targeted Compound Library
HY-L089
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Anti-Cancer Natural Product Library
HY-L107
-
Antiviral Traditional Chinese Medicine Active Compound Library
HY-L113
-
Plant-Sourced Natural Product Library
HY-L115
-
Human Metabolite Library
HY-L123
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Cancer Stem Cells Compound Library
HY-L135
-
Coagulation and Anti-coagulation Compound Library
HY-L136
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Cytokine Inhibitors Library
HY-L161
-
Cell Death Library
HY-L162
-
Serine/Threonine Kinase Inhibitor Library
HY-L164
-
Anti-Hematopathy Compound Library
HY-L171
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
Mitophagy Compound Library
HY-L180
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Bioactive Compound Library
HY-L001
-
Anti-Brain Cancer Compound Library
HY-L188
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library
HY-L223
-
Posttranslational Modification Library
HY-L226
-
Mongolian Medicine Compound Library
HY-L238
-
Quinones Library
HY-L243
-
Natural Product Diversity Scaffold Library
HY-L245
-
Fungal-Sourced Compound Library
HY-L253
-
Mass Spectrometry Natural Product Library
HY-L262
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Epigenetics Compound Library
HY-L005
-
Kinase Inhibitor Library
HY-L009
-
Protein Tyrosine Kinase Compound Library
HY-L016
-
TGF-beta/Smad Compound Library
HY-L018
-
Natural Product Library
HY-L021
-
Anti-Cancer Compound Library
HY-L025
-
Antiviral Compound Library
HY-L027
Publications Citing Use of MedChemExpress (MCE) Hypocrellin A
MoreVoir tous les produits spécifiques à Isoform Parasite
MoreVoir tous les produits spécifiques à Isoform VEGFR
More
Activité biologique
|
Leishmania |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| K562 | IC50 |
0.55 μM
Compound: 7
|
Cytotoxicity against human K562 cells treated for 4 hrs followed irradiated with invisible light for 1000 seconds by by MTT assay
Cytotoxicity against human K562 cells treated for 4 hrs followed irradiated with invisible light for 1000 seconds by by MTT assay
|
[PMID: 22276650] |
| K562 | IC50 |
7.47 μM
Compound: 7
|
Cytotoxicity against human K562 cells after 24 hrs by MTT assay
Cytotoxicity against human K562 cells after 24 hrs by MTT assay
|
[PMID: 22276650] |
Hypocrellin A (150 nM; 24 h) significantly reduces the release of VEGF and ET-1 from human umbilical vein endothelial cells (HUVECs) incubated in glucose (20 mM)[1].
Hypocrellin A shows good activity against Candida albicans (IC50=0.65 μg/ml) and moderates activity against Staphylococcus aureus, MRSA, Pseudomonas aeruginosa, and Mycobacterium intracellularis[4].
Hypocrellin A (0.055-5.5 µM) loses the infectivity of both HIV-1 and VSV in a concentration-dependent manner when treats with 1 J/cm2 white light[5].
Hypocrellin A (5 µM; 6 h) increases the secretion of multiple anti-angiogenic factors in LN229 glioma, U937 macrophages and SVHCEC endothelial cells after photochemotherapy[6].
Hypocrellin A (0.25-1 µM; 48 h) has a negative impact on cell viability, migration, invasion and apoptosis of three non-small cell lung cancer cells, H460, PC-9 and H1975[8].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human umbilical vein endothelial cells (HUVECs) incubated in glucose (20 mM)
-
Concentration:150 nM
-
Incubation Time:24 h
-
Result:Reduced VEGF protein expression.
-
Cell Line:LN229 glioma, U937 macrophages, and SVHCEC endothelial cells
-
Concentration:5 µM
-
Incubation Time:6 h
-
Result:Induced production of roangiogenic VEGF (vascular endothelial growth factor) and of antiangiogenic sFlt-1, angiostatin, p43, allograft inflammatory factor-1, and connective tissue growth factor.
-
Cell Line:H460, PC-9 and H1975 cell lines
-
Concentration:0.25, 0.5 and 1 µM
-
Incubation Time:48 h
-
Result:The IC50 values for H460, PC-9 and H1975 cell lines were 0.2706, 0.6223 and 0.2223 µM, respectively.
-
Cell Line:H460, PC-9 and H1975 cell lines
-
Concentration:0.25, 0.5 and 1 µM
-
Incubation Time:48 h
-
Result:Increased the expression levels of pro-apoptotic proteins BAX and Cl-PARP, and decreased the expression level of anti-apoptotic protein BCL-2.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:H460 cells were inoculated subcutaneously on the backs of BALB/c nude mice[8]
-
Dosage:2.5 and 5 mg/kg
-
Administration:i.p.; Inject once every two days for fourteen days
-
Result:Induced the expression of the pro-apoptotic protein BAX and inhibited the expression of the anti-apoptotic protein BCL-2 in NSCLC tumors.
Chemical Information
-
CAS No. 77029-83-5
-
Appearance Solid
-
Masse moléculaire 546.52
-
Formule C30H26O10
-
Color Brown to red
-
SMILES
COC(C1=O)=C2C3=C(C1=C(C=C4OC)O)C4=C(C(OC)=CC(O)=C56)C5=C3C(CC(C)(O)C2C(C)=O)=C(OC)C6=O
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
Solvant et solubilité
DMSO : 16.67 mg/mL (30.50 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (4.57 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (291 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Dang L, et al. Effects of hypocrellin A on expression of vascular endothelial growth factor and endothelin-1 in human umbilical endothelial cells. Am J Chin Med. 2007;35(4):713-23. [Content Brief]
[2]. Ma YJ, et al. Enhanced Production of Hypocrellin A in Submerged Cultures of Shiraia bambusicola by Red Light. Photochem Photobiol. 2019 May;95(3):812-822. [Content Brief]
[3]. Fehr MJ, et al. Roles of oxygen and photoinduced acidification in the light-dependent antiviral activity of hypocrellin A. Biochemistry. 1995 Dec 5;34(48):15845-8. [Content Brief]
[4]. Ma G, et al. Antimicrobial and antileishmanial activities of hypocrellins A and B. Antimicrob Agents Chemother. 2004 Nov;48(11):4450-2. [Content Brief]
[5]. Hirayama, et al. "Photoinactivation of virus infectivity by hypocrellin A." Photochemistry and photobiology 66.5 (1997): 697-700. [Content Brief]
[6]. Deininger, et al. "Release of regulators of angiogenesis following Hypocrellin-A and-B photodynamic therapy of human brain tumor cells." Biochemical and Biophysical Research Communications 298.4 (2002): 520-530. [Content Brief]
[7]. Yujie, et al. "Photodynamic antimicrobial activity of hypocrellin A." Journal of Photochemistry and Photobiology B: Biology 103.1 (2011): 29-34. [Content Brief]
[8]. Yang, et al. "Hypocrellin A exerts antitumor effects by inhibiting the FGFR1 signaling pathway in non-small cell lung cancer." Phytomedicine 97 (2022): 153924. [Content Brief]
[9]. Guo, et al. "Evaluation of hypocrellin A-loaded lipase sensitive polymer micelles for intervening methicillin-resistant Staphylococcus Aureus antibiotic-resistant bacterial infection." Materials Science and Engineering: C 106 (2020): 110230. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8298 mL | 9.1488 mL | 18.2976 mL | 45.7440 mL |
| 5 mM | 0.3660 mL | 1.8298 mL | 3.6595 mL | 9.1488 mL | |
| 10 mM | 0.1830 mL | 0.9149 mL | 1.8298 mL | 4.5744 mL | |
| 15 mM | 0.1220 mL | 0.6099 mL | 1.2198 mL | 3.0496 mL | |
| 20 mM | 0.0915 mL | 0.4574 mL | 0.9149 mL | 2.2872 mL | |
| 25 mM | 0.0732 mL | 0.3660 mL | 0.7319 mL | 1.8298 mL | |
| 30 mM | 0.0610 mL | 0.3050 mL | 0.6099 mL | 1.5248 mL |
Hypocrellin A Related Classifications
HY-N2575 Related Classifications
Powered by Bioz